IgG4-related disease (IgG4-RD) is a chronic inflammatory condition that can strike virtually any organ in the body, causing swelling, tissue scarring, and, if untreated, permanent damage. It was not even recognized as a single unified disease until the early 2000s, yet it has since been identified worldwide and described in considerable clinical detail.1The Lancet Rheumatology. IgG4-related disease Despite affecting multiple organs with seemingly unrelated symptoms, IgG4-RD follows a recognizable pattern under the microscope and responds to a limited set of treatments, which is what ties the whole syndrome together.
How Doctors Came to Recognize IgG4-RD
For decades, physicians encountered puzzling cases of organ swelling and fibrosis that did not fit neatly into any known category. A swollen pancreas would be called autoimmune pancreatitis. A mass in the salivary gland was labeled Küttner’s tumor or Mikulicz’s disease. Scarring around the aorta was described as idiopathic retroperitoneal fibrosis. Each of these seemed like a different disease in a different specialty. The breakthrough came when researchers noticed that tissue biopsies from many of these seemingly unrelated conditions shared a striking feature: an abundance of immune cells (plasma cells) producing a specific subclass of antibody called immunoglobulin G4. Autoimmune pancreatitis, once considered a standalone condition, became the prototypical example of this newly unified disease entity.2PubMed. IgG4-related disease: historical overview and pathology of hematological disorders That recognition transformed the field: conditions that had been managed separately by gastroenterologists, rheumatologists, ophthalmologists, and surgeons were now understood as different expressions of one systemic process.
What Drives the Disease
IgG4-RD arises from an abnormal immune response involving both the adaptive and innate arms of the immune system. Multiple types of immune cells participate. T helper type 2 cells, regulatory T cells, T follicular helper cells, and certain B cell populations are all implicated, alongside innate players like macrophages, mast cells, and complement proteins.3PubMed Central. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis One of the more revealing discoveries involves a population of CD4+ cytotoxic T cells that express a surface marker called SLAMF7. These cells accumulate in both the bloodstream and affected tissues of patients with IgG4-RD, and they release signals that promote inflammation and tissue remodeling. When patients receive treatment that depletes B cells, these cytotoxic T cells decline in tandem with clinical improvement, suggesting they are not just bystanders but active participants in the disease.4Journal of Translational Autoimmunity. Immunological mechanism of IgG4-related disease – Section: CD4+ cytotoxic T lymphocytes
The antibody at the center of the disease’s name, IgG4, has unusual biological properties. Unlike other antibody subclasses, IgG4 molecules can exchange half of themselves with other IgG4 molecules, creating hybrid antibodies that bind two different targets. This “Fab-arm exchange” makes IgG4 functionally anti-inflammatory rather than pro-inflammatory.5PubMed. Mechanism of immunoglobulin G4 Fab-arm exchange That might sound paradoxical for a disease defined by too much IgG4, and in fact, whether IgG4 itself directly causes tissue damage or is more of a marker of the underlying immune process remains an open question. What is clear is that the immune activation driving IgG4-RD produces a distinctive signature under the microscope.
The Hallmarks Under the Microscope
Regardless of which organ is affected, biopsies from IgG4-RD lesions tend to show three cardinal features: a dense infiltrate of lymphocytes and plasma cells, a distinctive whirl-like pattern of scarring known as storiform fibrosis, and obliterative phlebitis, in which veins are gradually blocked by inflammatory cells and scar tissue.6PubMed. Consensus statement on the pathology of IgG4-related disease International classification criteria require these histological findings to be combined with a high ratio of IgG4-positive to total IgG-positive plasma cells (above 40%) and organ-specific thresholds for the absolute number of IgG4-positive cells.7PubMed Central. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis These tissue features are what unify the disease across organs: a mass in the pancreas and a mass in the orbit look remarkably similar under a microscope when IgG4-RD is the cause.
Who Gets It
IgG4-RD is uncommon but probably underdiagnosed, partly because it mimics so many other conditions. A claims-based study of commercially insured adults in the United States found a mean age at diagnosis of about 57 years, with roughly 58% of identified cases being female and about two-thirds White.8Annals of the Rheumatic Diseases. Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults Earlier literature, drawn primarily from Asian cohorts, has tended to report a male predominance, so the demographics may vary by population and by which organ is affected. The disease can also occur in younger adults, though it is rare in children.
Organs That IgG4-RD Targets
One of the most disorienting aspects of IgG4-RD is its breadth. The pancreas is the most studied site: IgG4-related autoimmune pancreatitis typically presents with painless jaundice, mild abdominal pain, and impaired pancreatic function.9PubMed Central. IgG4-related autoimmune pancreatitis and sclerosing cholangitis: A case report and literature review When the bile ducts are involved, the condition is called IgG4-related sclerosing cholangitis, which co-occurs with autoimmune pancreatitis in the vast majority of cases, estimated at 83% to 92%.10Gut and Liver. Classification and Diagnostic Criteria for IgG4-Related Sclerosing Cholangitis
Beyond the pancreas and bile ducts, the disease frequently affects the salivary and lacrimal (tear-producing) glands, sometimes causing visible facial swelling. In the head and neck, IgG4-RD can involve the orbital tissues, thyroid, pituitary gland, and even the meninges surrounding the brain. Pituitary involvement may cause hormonal deficiencies, headaches, and visual problems, while meningeal thickening can lead to hearing loss, sensory changes, or seizures.11PubMed Central. Intracranial Immunoglobulin G4-Related Disease Presented as Hypophysitis and Pachymeningitis: A Case Report Neurological involvement is relatively uncommon compared to other sites, but meningeal thickening and pituitary inflammation are the best-recognized neurological presentations.12PubMed Central. Neurological Manifestations of IgG4-Related Disease
The kidneys are another important target. The most common renal form is tubulointerstitial nephritis, where inflammatory cells and fibrosis infiltrate the tissue between the kidney’s filtering tubules.13PubMed Central. Overview of IgG4-Related Tubulointerstitial Nephritis and Its Mimickers If unrecognized, this can quietly erode kidney function over time.
The aorta and surrounding tissues are also vulnerable. IgG4-related aortitis affects the vessel wall itself, while periaortitis involves the tissue around the aorta and can overlap with retroperitoneal fibrosis. These vascular complications can lead to aortic wall thickening, inflammatory aneurysms, and even dissections.14Journal of Vascular Surgery Cases, Innovations and Techniques. A case of IgG4-related retroperitoneal fibrosis with significant involvement of the abdominal aorta—a clinical and diagnostic challenge Retroperitoneal fibrosis can encase the ureters, causing flank pain and kidney obstruction.15PubMed. Overview of IgG4-related aortitis and periaortitis. A decade since their first description Because patients are rarely symptomatic from early vascular involvement, these findings are sometimes discovered incidentally on imaging ordered for another reason.
Making the Diagnosis
Diagnosing IgG4-RD is genuinely challenging. There is no single test that confirms or rules it out, and the diagnosis rests on a combination of clinical presentation, blood work, imaging, and biopsy.
Blood Tests and Their Limits
Elevated serum IgG4 is the most widely used laboratory clue, but it is far from definitive. About 60% to 70% of patients have elevated levels, especially those with multi-organ involvement, meaning roughly 30% of people with confirmed IgG4-RD have completely normal serum IgG4.16PubMed Central. Mikulicz’s disease and Küttner’s tumor as manifestations of IgG4-related diseases: a review of the literature A meta-analysis of studies using the standard cutoff (around 135 to 144 mg/dL) found a pooled sensitivity of about 87% and specificity of about 83%.17PubMed Central. Diagnostic Value of Serum IgG4 for IgG4-Related Disease: A PRISMA-compliant Systematic Review and Meta-analysis Doubling the cutoff improved specificity to roughly 95% but dropped sensitivity to about 63%, meaning many true cases would be missed.18PubMed Central. Diagnostic Value of Serum IgG4 for IgG4-Related Disease: A PRISMA-compliant Systematic Review and Meta-analysis
Making things more complicated, elevated IgG4 levels are not exclusive to IgG4-RD. Conditions like certain vasculitides, lymphoma, and Castleman disease can also raise serum IgG4. Baseline IgG4 concentrations also vary by race and sex: Asian populations tend to have higher levels than White populations, and men tend to have higher levels than women.19PubMed. Clinical utility of serum IgG4 measurement Other laboratory abnormalities sometimes seen include low complement levels and elevated IgE or eosinophil counts, each found in roughly 30% of patients.20PubMed Central. Mikulicz’s disease and Küttner’s tumor as manifestations of IgG4-related diseases: a review of the literature
Imaging
Because IgG4-RD can involve organs silently, whole-body imaging plays an important role. PET/CT scanning, which highlights areas of increased metabolic activity, has proven useful for mapping all sites of disease involvement, including cardiovascular involvement that may not yet be causing symptoms.21PubMed Central. Semi-quantitative indices of 2-[(18)F]FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response A prospective study found characteristic patterns: diffusely elevated uptake in the pancreas and salivary glands, patchy uptake in retroperitoneal and vascular areas, and multi-organ involvement that did not look like cancer metastases. The scan also helped guide biopsy site selection and informed decisions about ureteral obstruction treatment. After two to four weeks of steroid therapy, about 72% of patients in that study showed complete metabolic remission on repeat scanning.22PubMed Central. Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective cohort study
Classification Criteria
In 2019, an international effort produced the ACR/EULAR classification criteria for IgG4-RD. These use a point-based system incorporating clinical, serological, histological, and radiological features. In validation testing, a threshold of 20 points yielded a specificity above 97% and sensitivity in the low-to-mid 80s.23PubMed. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease An external validation in a large Chinese cohort confirmed outstanding specificity (about 98%) with somewhat lower sensitivity (around 77%).24PubMed. The external validation of the 2019 ACR/EULAR classification criteria for IgG4-related disease in a large cohort from China The criteria deliberately prioritize specificity, because misdiagnosing a patient with IgG4-RD when they actually have cancer or another serious condition carries grave consequences. The trade-off is that some genuine IgG4-RD cases, particularly atypical presentations, will not meet the criteria and still require clinical judgment.
The Link Between IgG4-RD and Cancer
One of the more unsettling findings in recent years is that patients with IgG4-RD appear to face an elevated risk of developing certain cancers. A systematic review and meta-analysis found that overall cancer risk in IgG4-RD patients was roughly two and a half times that of the general population, with particularly elevated risks for pancreatic cancer and lymphoma.25PubMed Central. The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis A larger nationwide South Korean cohort study reported an even higher overall cancer risk (about four times that of the general population), with especially notable increases for pancreatic cancer, biliary tract cancer, and blood cancers like myelodysplastic syndrome and non-Hodgkin lymphoma. That study also found that cancer risk was highest during the first year after IgG4-RD diagnosis, suggesting that some early “IgG4-RD” diagnoses may in fact be cancer presenting with IgG4-mimicking features, or that the same immune dysregulation promotes both conditions early on.26PubMed Central. Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021
This overlap with cancer is also a diagnostic headache. Pancreatic cancer and bile duct cancer can look almost identical to IgG4-related pancreatitis and cholangitis on imaging, and the consequences of confusing the two run in both directions. Treating a cancer patient with steroids instead of surgery can be fatal, while subjecting an IgG4-RD patient to unnecessary major surgery carries its own serious risks. This is a major reason the classification criteria lean so heavily toward specificity, and why biopsy is often essential.
Treatment
Steroids remain the first line of therapy, and they work remarkably well in the short term. A systematic review covering over 1,200 patients found that 97% responded to glucocorticoid monotherapy.27PubMed Central. Therapeutic approach to IgG4-related disease A systematic review The problem is what happens next. Despite that impressive initial response rate, about a third of patients relapse.28PubMed Central. Therapeutic approach to IgG4-related disease A systematic review Relapse can occur even during ongoing low-dose steroid maintenance, as documented in cases of sclerosing cholangitis where patients developed severe bile duct narrowing again while still taking steroids.29PubMed Central. Relapsing immunoglobulin G4-related sclerosing cholangitis during maintenance treatment with low-dose steroids: a case report Long-term steroid use also brings its own well-known problems: weight gain, bone loss, diabetes, and immune suppression.
Rituximab, a drug that depletes B cells, has emerged as the most important steroid-sparing option. An open-label trial found that 97% of participants responded, with nearly half achieving complete remission at six months and about 40% remaining in complete remission at a year. Serum IgG4 levels dropped substantially even without concurrent steroids.30Annals of the Rheumatic Diseases. Rituximab for IgG4-related disease: a prospective, open-label trial A French nationwide study of 33 patients treated with rituximab found clinical responses in about 94% and glucocorticoid withdrawal in over half, though about 42% of responders eventually relapsed over about two years of follow-up. Patients who received scheduled maintenance rituximab infusions rather than waiting for relapse had significantly longer relapse-free survival.31PLoS ONE. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients A separate study comparing patients on six-monthly rituximab maintenance to those who stopped found a relapse rate of 29% in the maintenance group versus 100% in the group that discontinued, underscoring the importance of ongoing treatment in relapse-prone patients.32PubMed. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease
Looking ahead, newer targeted therapies are in development aimed at overcoming the limitations of both steroids and rituximab. Inebilizumab, an antibody targeting CD19 (a B cell marker), is among those being studied, with the hope of reducing organ damage and fibrosis more effectively while minimizing side effects.33PubMed. Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials
Tracking Disease Activity and Organ Damage
Because IgG4-RD tends to wax and wane, standardized tools for monitoring disease activity are essential. The IgG4-RD Responder Index (RI) has been validated internationally as a reliable way to measure whether a patient is improving, stable, or flaring. It tracks organ-by-organ activity and has been shown to consistently detect treatment responses across multiple specialties.34PubMed Central. An International, Multi-Specialty Validation Study of the IgG4-Related Disease Responder Index More recently, a separate Damage Index covering 14 organ system domains has been developed to capture irreversible harm that accumulates over time, such as fibrosis or glandular destruction that persists even after inflammation subsides. This index showed good reliability across different raters and a sensitivity above 85% for detecting increased damage.35BMJ. The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium
The distinction between active inflammation and accumulated damage matters enormously for treatment decisions. Steroids and rituximab can quiet active inflammation, but they cannot reverse fibrosis once it has set in. A patient whose kidneys are scarred or whose bile ducts are permanently narrowed will not recover that function simply from controlling the immune process going forward. This is why early recognition and treatment matter so much: every month of unchecked disease activity is a month during which fibrosis may be progressing silently in one or more organs. It also explains why some patients remain symptomatic even after their inflammatory markers normalize, since the damage already done does not reverse with immunosuppression.
Why IgG4-RD Is So Often Misdiagnosed
Few diseases impersonate as many other conditions as IgG4-RD does. A pancreatic mass raises immediate concern for pancreatic cancer. Salivary gland enlargement prompts workup for Sjögren’s syndrome or lymphoma. Retroperitoneal fibrosis may be attributed to prior radiation or medication side effects. Orbital swelling gets investigated as thyroid eye disease. In each of these scenarios, IgG4-RD sits on the differential diagnosis but is often not considered until other possibilities have been exhausted, sometimes after unnecessary surgery.
The lack of a perfectly sensitive or specific blood test compounds the problem. A normal serum IgG4 level does not rule out the disease, and an elevated level does not confirm it.36PubMed. Clinical utility of serum IgG4 measurement Even tissue biopsy requires an experienced pathologist, because the histological features of IgG4-RD can overlap with other inflammatory and fibrotic conditions. Awareness is probably the single biggest factor in getting the diagnosis right: a clinician who has IgG4-RD on their mental checklist is far more likely to order the right stains on a biopsy or to check a serum IgG4 level in a patient with unexplained multi-organ inflammation.
For patients navigating this diagnostic maze, the practical takeaway is that IgG4-RD should be considered whenever inflammatory masses, unexplained organ enlargement, or fibrotic changes appear in more than one organ system, particularly when the usual explanations do not quite fit. A second opinion from a center with experience in IgG4-RD can be the difference between years of diagnostic uncertainty and a clear path to treatment.